Effects of serum bilirubin on atherosclerotic processes

Annals of Medicine

Volumn 46, Issue 3, 2014, Pages 138-147

  Kang, Seung Joo ^a   Lee, Changhyun ^a   Kruzliak, Peter ^b  

^a Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Atherosclerosis; Bilirubin; Cardiovascular disease

Indexed keywords

BILIRUBIN; LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; CARBON MONOXIDE; HEME;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BILIRUBIN BLOOD LEVEL; BIOCHEMICAL COMPOSITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CHEMOTAXIS; CHOLESTEROL METABOLISM; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HUMAN; LEUKOCYTE ADHERENCE INHIBITION; METABOLIC SYNDROME X; MITOSIS INHIBITION; MONOCYTE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE; ANIMAL; BLOOD; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; BILIRUBIN; CARBON MONOXIDE; HEME; HUMANS;

EID: 84899852226     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.895588     Document Type: Review

References (82)

1. Vitek L, Schwertner HA. The heme catabolic pathway and its protective Effects on oxidative stress-mediated diseases. Adv Clin Chem. 2007; 43: 1-57.
2. Vitek L, Ostrow JD. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des. 2009; 15: 2869-83.
3. Balla J, Vercellotti GM, Jeney V, Yachie A, Varga Z, Eaton JW, et al. Heme, heme oxygenase and ferritin in vascular endothelial celLinjury. Mol Nutr Food Res. 2005; 49: 1030-43.
4. Piantadosi CA. Carbon monoxide, reactive oxygen signaling, and oxidative stress. Free Radic Biol Med. 2008; 45: 562-9.
5. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reducedexpression of bilirubin UDP- glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995; 333: 1171-5.
6. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol. 1997; 37: 517-54.
7. Nath KA. The functional signifi cance of induction of heme oxygenase by oxidant stress. J Lab Clin Med. 1994; 123: 461-3.
8. Pimstone NR, Tenhunen R, Seitz PT, Marver HS, Schmid R. The enzymatic degradation of hemoglobin to bile pigments by macrophages. J Exp Med. 1971; 133: 1264-81.
9. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006; 86: 583-650.
10. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiologicaLimportance. Science. 1987; 235: 1043-6.
11. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA. 2002; 99: 16093-8.
12. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, et al. Gilbert syndrome and ischemic heart disease: a protective Effect of elevated bilirubin levels. Atherosclerosis. 2002; 160: 449-56.
13. Vitek L, Kraslova I, Muchova L, Novotny L, Yamaguchi T. Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome. J Gastroenterol Hepatol. 2007; 22: 841-5.
14. Mazzone GL, Rigato I, Ostrow JD, Bossi F, Bortoluzzi A, Sukowati CH, et al. Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun. 2009; 386: 338-44.
15. Tapan S, Dogru T, Tasci I, Ercin C N, Ozgurtas T, Erbil M K. Soluble CD40 ligand and soluble P-selectin levels in Gilbert's syndrome: a link to protection against atherosclerosis? Clin Biochem. 2009; 42: 791-5.
16. Basiglio CL, Arriaga SM, Pelusa HF, Almara AM, Roma MG, Mottino AD. Protective role oFunconjugated bilirubin on complementmediated hepatocytolysis. Biochim Biophys Acta. 2007; 1770: 1003-10.
17. Hwang HJ, Lee SW, Kim SH. Relationship between bilirubin and C-reactive protein. Clin Chem Lab Med. 2011; 49: 1823-8.
18. Yoshino S, Hamasaki S, Ishida S, Kataoka T, Yoshikawa A, Oketani N, et al. Relationship between bilirubin concentration, coronarYendothelial function, and infl ammatory stress in overweight patients. J Atheroscler Th romb. 2011; 18: 403-12.
19. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994; 40: 18-23.
20. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Th romb Vasc Biol. 1996; 16: 250-5.
21. Schwertner HA. Association of smoking and low serum bilirubin antioxidant concentrations. Atherosclerosis. 1998; 136: 383-7.
22. Schwertner HA, Fischer JR, Jr. Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease. Atherosclerosis. 2000; 150: 381-7.
23. Tanaka M, Fukui M, Tomiyasu K, Akabame S, Nakano K, Hasegawa G, et al. Low serum bilirubin concentration is associated with coronary artery calcifi cation (CAC). Atherosclerosis. 2009; 206: 287-91.
24. Kang SJ, Kim D, Park HE, Chung GE, Choi SH, Choi SY, et al. Elevated serum bilirubin levels are inversely associated with coronary artery atherosclerosis. Atherosclerosis. 2013; 230: 242-8.
25. Gullu H, Erdogan D, Tok D, Topcu S, Caliskan M, Ulus T, et al. High serum bilirubin concentrations preserve coronary fLow reserve and coronary microvascular functions. Arterioscler Th romb Vasc Biol. 2005; 25: 2289-94.
26. Schwertner H A, Vitek L. Gilbert syndrome, UGT1A12 8 allele, and cardiovascular disease risk: possible protective Effects and therapeutic applications of bilirubin. Atherosclerosis. 2008; 198: 1-11.
27. Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham off spring study. Am J Cardiol. 2001; 87: 1196-200; A1194, 1197.
28. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood). 2003; 228: 568-71.
29. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke. 2009; 40: 3422-7.
30. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med. 2008; 121: 781-8 e781.
31. Vitek L, Novotny L, Sperl M, Holaj R, Spacil J. The inverse association of elevated serum bilirubin levels witHsubclinical carotid atherosclerosis. Cerebrovasc Dis. 2006; 21: 408-14.
32. Erdogan D, Gullu H, Yildirim E, Tok D, Kirbas I, Ciftci O, et al. Low serum bilirubin levels are independently and inversely related to impaired fLow-mediated vasodilation and increased carotid intimamedia thickness in both men and women. Atherosclerosis. 2006; 184: 431-7.
33. Dullaart RPF, Kappelle PJWH, de Vries R. Lower carotid intima media thickness is predicted by higher serum bilirubin in noth non-diabetic and Type 2 diabetic subjects. Clin Chim Acta. 2012; 414: 161-5.
34. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National HealtHand Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Th romb Vasc Biol. 2008; 28: 166-72.
35. Lin LY, Kuo HK, Hwang JJ, Lai LP, Chiang FT, Tseng CD, et al. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis. 2009; 203: 563-8.
36. Cheriyath P, Gorrepati VS, Peters I, Nookala V, Murphy ME, Srouji N, et al. High total bilirubin as a protective factor for diabetes mellitus: an analysis of NHANES data from 1999-2006. J Clin Med Res. 2010; 2: 201-6.
37. Huang SS, Huang PH, Leu HB, Wu TC, Lin SJ, Chen JW. Serum bilirubin predicts long-term clinical outcomes in patients with cardiac syndrome X. Heart. 2010; 96: 1227-32.
38. Ong KL, Wu BJ, Cheung BM, Barter PJ, Rye KA. Association of lower total bilirubin level with statin usage: the United States National HealtHand Nutrition Examination Survey 1999-2008. Atherosclerosis. 2011; 219: 728-33.
39. Stocker R, Keaney JF Jr. Role of oxidative modifi cations in atherosclerosis. Physiol Rev. 2004; 84: 1381-478.
40. Stocker R, Perrella MA. Heme oxygenase-1: a novel drug target for atherosclerotic diseases? Circulation. 2006; 114: 2178-89.
41. Stocker R. Antioxidant activities of bile pigments. Antioxid Redox Signal. 2004; 6: 841-9.
42. Clark J E, Foresti R, Green C J, Motterlini R. Dynamics of heme oxygenase-1 expression and bilirubin production in cellular protection against oxidative stress. Biochem J. 2000; 348(Pt 3): 615-19.
43. Wu TW, Fung KP, Yang CC. Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 1994; 54: P477-81.
44. Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA. 2009; 106: 5171-6.
45. Dennery PA, McDonagh AF, Spitz DR, Rodgers PA, Stevenson DK. Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radic Biol Med. 1995; 19: 395-404.
46. Benitez S, Sanchez-Quesada JL, Lucero L, Arcelus R, Ribas V, Jorba O, et al. Changes in low-density lipoprotein electronegativity and oxidizability aft er aerobic exercise are related to the increase in associated non-esterifi ed fatty acids. Atherosclerosis. 2002; 160: 223-32.
47. Ishikawa K, Navab M, Leitinger N, Fogelman AM, Lusis AJ. Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL. J Clin Invest. 1997; 100: 1209-16.
48. Morita T, Imai T, Yamaguchi T, Sugiyama T, Katayama S, Yoshino G. Induction of heme oxygenase-1 in monocytes suppresses angiotensin II-elicited chemotactic activity through inhibition of CCR2: role of bilirubin and carbon monoxide generated by the enzyme. Antioxid Redox Signal. 2003; 5: 439-47.
49. Keshavan P, Deem TL, Schwemberger SJ, Babcock GF, Cook-Mills JM, Zucker SD. Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J Immunol. 2005; 174: 3709-18.
50. Nakayama M, Takahashi K, Komaru T, Fukuchi M, Shioiri H, Sato K, et al. Increasedexpression of heme oxygenase-1 and bilirubin accumulation in foam cells of rabbit atherosclerotic lesions. Arterioscler Th romb Vasc Biol. 2001; 21: 1373-7.
51. Hayashi S, Takamiya R, Yamaguchi T, Matsumoto K, Tojo SJ, Tamatani T, et al. Induction of heme oxygenase-1 suppresses venular leukocyte adhesion elicited by oxidative stress: role of bilirubin generated by the enzyme. Circ Res. 1999; 85: 663-71.
52. Kawamura K, Ishikawa K, Wada Y, Kimura S, Matsumoto H, Kohro T, et al. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Th romb Vasc Biol. 2005; 25: 155-60.
53. Mazzone GL, Rigato I, Ostrow JD, Tiribelli C. Bilirubin Effect on endothelial adhesion molecules expression is mediated by the NF-kappaB signaling pathway. Biosci Trends. 2009; 3: 151-7.
54. Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, et al. Bilirubin: a naturaLinhibitor of vascular smooth muscle cell proliferation. Circulation. 2005; 112: 1030-9.
55. Ollinger R, Yamashita K, Bilban M, Erat A, Kogler P, Thomas M, et al. Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle. 2007; 6: 39-43.
56. Peyton KJ, Shebib AR, Azam MA, Liu XM, Tulis DA, Durante W. Bilirubin inhibits neointima formation and vascular smooth muscle cell proliferation and migration. Front Pharmacol. 2012; 3: 48.
57. Stoeckius M, Erat A, Fujikawa T, Hiromura M, Koulova A, Otterbein L, et al. Essential roles of Raf/extracellular signal-regulated kinase/mitogen- activated protein kinase pathway, YY1, and Ca2 infl uXin growth arrest of human vascular smooth muscle cells by bilirubin. J Biol Chem. 2012; 287: 15418-26.
58. Kuwano T, Miura S, Shirai K, Ike A, Mori K, Shimizu T, et al. Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: a new look at an old molecule. J Atheroscler Th romb. 2011; 18: 574-83.
59. Rodella L, Lamon B D, Rezzani R, Sangras B, Goodman A I, Falck JR, et al. Carbon monoxide and biliverdin prevent endothelial cell sloughing in rats with type I diabetes. Free Radic Biol Med. 2006; 40: 2198-205.
60. Wei Y, Liu XM, Peyton KJ, Wang H, Johnson FK, Johnson RA, et al. Hypochlorous acid-induced heme oxygenase-1 gene expression promotes human endothelial cell survival. Am J Physiol Cell Physiol. 2009; 297: C907-15.
61. Kumar V, Butcher SJ, Oorni K, Engelhardt P, Heikkonen J, Kaski K, et al. Three-dimensional cryoEM reconstruction of native LDL particles to 16A resolution at physiological body temperature. PLoS One. 2011; 6: e18841.
62. Levinson SS. Relationship between bilirubin, apolipoprotein B, and coronary artery disease. Ann Clin Lab Sci. 1997; 27: 185-92.
63. O' Kane MJ, Lynch PL, Callender ME, Trimble ER. Abnormalities of serum apo A1 containing lipoprotein particles in patients with primary biliary cirrhosis. Atherosclerosis. 1997; 131: 203-10.
64. Zhang N, Ahsan M H, Purchio A F, West D B. Serum amyloid A-luciferase transgenic mice: response to sepsis, acute arthritis, and contact hypersensitivity and the Effects of proteasome inhibition. J Immunol. 2005; 174: 8125-34.
65. Dullaart RP, de Boer JF, Annema W, Tietge UJ. The inverse relation of HDL anti-oxidative functionality with serum amyloid a is lost in metabolic syndrome subjects. Obesity (Silver Spring). 2013; 21: 361-6.
66. Deetman PE, Bakker SJ, Dullaart RP. High sensitive C-reactive protein and serum amyloid A are inversely related to serum bilirubin: Effect-modifi cation by metabolic syndrome. Cardiovasc Diabetol. 2013; 12: 166.
67. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, et al. Remnant-like particle (RLP) cholesteroLis an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001; 154: 229-36.
68. Abraham NG, Kappas A. Heme oxygenase and the cardiovascularrenal system. Free Radic Biol Med. 2005; 39: 1-25.
69. Yet SF, Layne MD, Liu X, Chen YH, Ith B, Sibinga NE, et al. Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J. 2003; 17: 1759-61.
70. Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, et al. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med. 2001; 7: 693-8.
71. Yet SF, Tian R, Layne MD, Wang ZY, Maemura K, Solovyeva M, et al. Cardiac-specifi c expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res. 2001; 89: 168-73.
72. Poss KD, Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci USA. 1997; 94: 10919-24.
73. Benallaoua M, Francois M, Batteux F, Thelier N, Shyy JY, Fitting C, et al. Pharmacologic induction of heme oxygenase 1 reduces acute infl ammatory arthritis in mice. Arthritis Rheum. 2007; 56: 2585-94.
74. Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, et al. Carbon monoxide has anti-infl ammatory Effects involving the mitogen-activated protein kinase pathway. Nat Med. 2000; 6: 422-8.
75. Stender S, Frikke-Schmidt R, Nordestgaard BG, Grande P, Tybjaerg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a metaanalysis. J Intern Med. 2013; 273: 59-68.
76. Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol. 2003; 38: 107-17.
77. Bosma PJ, van der Meer IM, Bakker CT, Hofman A, Paul-Abrahamse M, Witteman JC. UGT1A1 28 allele and coronary heart disease: the Rotterdam Study. Clin Chem. 2003; 49: 1180-1.
78. Schwertner HA. Bilirubin concentration, UGT1A1 28 polymorphism, and coronary artery disease. Clin Chem. 2003; 49: 1039-40.
79. Gajdos V, Petit FM, Perret C, Mollet-Boudjemline A, Colin P, Capel L, et al. Further evidence that the UGT1A1 28 allele is not associated with coronary heart disease: The ECTIM Study. Clin Chem. 2006; 52: 2313-14.
80. Lin JP, O' Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, et al. Association between the UGT1A1 28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006; 114: 1476-81.
81. Tuzun F, Kumral A, Duman N, Ozkan H. Breast milk jaundice: Effect of bacteria present in breast milk and infant feces. J Pediatr Gastroenterol Nutr. 2013; 56: 328-32.
82. Daniel H, Gholami A M, Berry D, Desmarchelier C, Hahne H, Loh G, et al. High-fat diet alters gut microbiota physiology in mice. ISME J. 2014; 8: 295-308.